Phase 1/2 study of CYWC628 to treat diabetic foot ulcers
Latest Information Update: 23 Sep 2024
At a glance
- Drugs CYW 628 (Primary)
- Indications Diabetic foot ulcer
- Focus Therapeutic Use
- 23 Sep 2024 New trial record
- 19 Sep 2024 According to a FibroBiologics media release, the company announced that it has engaged with Southern Star Research to provide clinical research organization (CRO) services for FibroBiologics in Australia. Initial CRO services will include preparatory work for a Phase 1/2 clinical trial utilizing product candidate, CYWC628, to treat diabetic foot ulcers.